Russia has announced the development of what has been described as an anti-aging “vaccine,” though experts clarify it is technically a gene therapy drug designed to slow cellular aging.
The project, reported by @BRICSinfo, is being led by Russia’s Institute of Biology of Ageing and Medicine and is backed by a multi-billion dollar budget, with a potential rollout projected between 2028 and 2030.
According to available details, the therapy focuses on blocking the RAGE receptor—short for Receptor for Advanced Glycation End-products—which plays a key role in inflammation and age-related cellular damage.
By targeting this pathway, researchers aim to reduce chronic inflammation, oxidative stress, and the accumulation of senescent cells, all of which are associated with aging and age-related diseases.
Although described in headlines as a “vaccine,” the treatment functions more like a gene-based therapeutic intervention rather than a traditional preventive vaccine.
Scientists involved in the project reportedly believe that modifying or suppressing RAGE-related signaling could help slow degenerative processes at the cellular level, potentially extending healthspan—the number of years a person lives in good health.
The initiative reflects growing global interest in longevity science, an area that has attracted increasing public and private investment.
Researchers worldwide are studying methods to delay biological aging, including senolytic drugs, gene editing technologies, and metabolic interventions. However, many such therapies remain in early experimental stages.
Russian officials have reportedly allocated significant funding to accelerate research and development, signaling strategic interest in biotechnology and preventive medicine. If successful, the treatment could be positioned not only as a medical innovation but also as a symbol of scientific advancement….See More
Leave a Reply